Genmab CEO: Tivdak launch has provided important experience for future treatments

The launch of Tivdak in the US, which is currently taking place, is providing Genmab with important experiences ahead of the launch of epcoritamab with partner Abbvie later this year, says company CEO Jan van de Winkel.

Genmab CEO Jan van de Winkel | Photo: Stine Bidstrup/ERH

Tivdak, which was approved as a cervical cancer treatment in the US last year, is the first drug that Danish biotech company Genmab has chosen to sell and market itself.

Although Tivdak’s indication makes it only relevant for a few thousand patients, CEO of Genmab Jan van de Winkel doesn’t shy away from its importance.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs